BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
Titel:
BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with estrogen receptor-positive advanced or metastatic breast cancer, and in a PIK3CA mutant sub-population
Auteur:
Turner, N.C. Alarcón, E. Armstrong, A.C. Philco, M. López Chuken, Y.A. Sablin, M.-P. Tamura, K. Gómez Villanueva, A. Pérez-Fidalgo, J.A. Cheung, S.Y.A. Corcoran, C. Cullberg, M. Davies, B.R. de Bruin, E.C. Foxley, A. Lindemann, J.P.O. Maudsley, R. Moschetta, M. Outhwaite, E. Pass, M. Rugman, P. Schiavon, G. Oliveira, M.